FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2135198311> ?p ?o ?g. }

• W2135198311 endingPage "21" @default.
• W2135198311 startingPage "21" @default.
• W2135198311 abstract "The outcome of chemotherapy in breast cancer is strongly influenced by multidrug resistance (MDR). Several surrogate markers of chemoresistance have been identified including - CD24 (cluster differentiation 24) expression, stem cell growth factor (SCF), B-cell lymphocyte protein 2 (Bcl-2) and annexin V. The present study aimed to examine the expression of CD24 in the sensitive breast cancer cell line MCF-7 (Michigan Foudation-7) and MCF-7/adriamycin resistant (MCF-7/AdrRes) cells, and, if minimal effective doses of the anthracycline drug adriamycin (0.579 μM and 88.2 μM) would be enhanced by the antibody to SCF (anti-SCF). CD24 expression was analysed by flow cytometry. Both Bcl-2 and annexin V protein expression were quantitatively assessed by the enzyme-linked immunosorbent assay (ELISA). In MCF-7/AdrRes cells the expression of CD24 was significantly higher compared to MCF-7 cells, 86.6% and 16.3% (p < 0.001), respectively. Bcl-2 expression was significantly increased in the presence of adriamycin and SCF (p < 0.038) and decreased in the presence of adriamycin and anti-SCF. When adriamycin, anti-SCF and SCF were combined or when adriamycin was used alone the decrease in Bcl-2 expression was insignificantly altered. In the presence of both adriamycin and SCF the expression of annexin V was decreased. However, it was significantly increased in the presence of adriamycin and anti-SCF (p < 0.042), as well as adriamycin, anti-SCF and SCF combined. In MCF-7 cells the effect of adriamycin alone or with either SCF, anti-SCF or anti-SCF or SCF combined, did not significantly alter the expression of Bcl-2. However, in the presence of both adriamycin and SCF the expression of annexin V was decreased, but was significantly increased in the presence of adriamycin and anti-SCF (p < 0.001), adriamycin, anti-SCF and SCF combined and adriamycin alone. Our results demonstrate that anti-SCF with low dose of adriamycin reduces Bcl-2 expression in MCF-7/AdrRes cells and increases annexin V expression in both MCF7/AdrRes and MCF-7 cells. Adding anti-SCF to the chemotherapeutic regime of adriamycin may strongly enhance its chemotherapeutic effect in the treatment of patients with breast cancer." @default.
• W2135198311 created "2016-06-24" @default.
• W2135198311 creator A5022718604 @default.
• W2135198311 creator A5026699102 @default.
• W2135198311 creator A5049176501 @default.
• W2135198311 creator A5049719379 @default.
• W2135198311 creator A5072499426 @default.
• W2135198311 date "2012-01-01" @default.
• W2135198311 modified "2023-09-27" @default.
• W2135198311 title "The stem cell factor antibody enhances the chemotherapeutic effect of adriamycin on chemoresistant breast cancer cells" @default.
• W2135198311 cites W1968860440 @default.
• W2135198311 cites W2003912692 @default.
• W2135198311 cites W2018360235 @default.
• W2135198311 cites W2034269086 @default.
• W2135198311 cites W2043762266 @default.
• W2135198311 cites W2044920175 @default.
• W2135198311 cites W2054022422 @default.
• W2135198311 cites W2062069198 @default.
• W2135198311 cites W2083667028 @default.
• W2135198311 cites W2138734774 @default.
• W2135198311 cites W2148103659 @default.
• W2135198311 cites W2149751455 @default.
• W2135198311 cites W2162760540 @default.
• W2135198311 cites W2166291746 @default.
• W2135198311 cites W2169302611 @default.
• W2135198311 doi "https://doi.org/10.1186/1475-2867-12-21" @default.
• W2135198311 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3853129" @default.
• W2135198311 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24228731" @default.
• W2135198311 hasPublicationYear "2012" @default.
• W2135198311 type Work @default.
• W2135198311 sameAs 2135198311 @default.
• W2135198311 citedByCount "7" @default.
• W2135198311 countsByYear W21351983112013 @default.
• W2135198311 countsByYear W21351983112014 @default.
• W2135198311 countsByYear W21351983112016 @default.
• W2135198311 countsByYear W21351983112017 @default.
• W2135198311 crossrefType "journal-article" @default.
• W2135198311 hasAuthorship W2135198311A5022718604 @default.
• W2135198311 hasAuthorship W2135198311A5026699102 @default.
• W2135198311 hasAuthorship W2135198311A5049176501 @default.
• W2135198311 hasAuthorship W2135198311A5049719379 @default.
• W2135198311 hasAuthorship W2135198311A5072499426 @default.
• W2135198311 hasBestOaLocation W21351983111 @default.
• W2135198311 hasConcept C109159458 @default.
• W2135198311 hasConcept C109541995 @default.
• W2135198311 hasConcept C121608353 @default.
• W2135198311 hasConcept C126322002 @default.
• W2135198311 hasConcept C153911025 @default.
• W2135198311 hasConcept C159654299 @default.
• W2135198311 hasConcept C185592680 @default.
• W2135198311 hasConcept C2022786 @default.
• W2135198311 hasConcept C203014093 @default.
• W2135198311 hasConcept C2776694085 @default.
• W2135198311 hasConcept C2776802502 @default.
• W2135198311 hasConcept C2779492189 @default.
• W2135198311 hasConcept C2781303535 @default.
• W2135198311 hasConcept C28328180 @default.
• W2135198311 hasConcept C2994423619 @default.
• W2135198311 hasConcept C30345302 @default.
• W2135198311 hasConcept C502942594 @default.
• W2135198311 hasConcept C530470458 @default.
• W2135198311 hasConcept C553184892 @default.
• W2135198311 hasConcept C71924100 @default.
• W2135198311 hasConcept C86803240 @default.
• W2135198311 hasConcept C88634738 @default.
• W2135198311 hasConcept C95444343 @default.
• W2135198311 hasConceptScore W2135198311C109159458 @default.
• W2135198311 hasConceptScore W2135198311C109541995 @default.
• W2135198311 hasConceptScore W2135198311C121608353 @default.
• W2135198311 hasConceptScore W2135198311C126322002 @default.
• W2135198311 hasConceptScore W2135198311C153911025 @default.
• W2135198311 hasConceptScore W2135198311C159654299 @default.
• W2135198311 hasConceptScore W2135198311C185592680 @default.
• W2135198311 hasConceptScore W2135198311C2022786 @default.
• W2135198311 hasConceptScore W2135198311C203014093 @default.
• W2135198311 hasConceptScore W2135198311C2776694085 @default.
• W2135198311 hasConceptScore W2135198311C2776802502 @default.
• W2135198311 hasConceptScore W2135198311C2779492189 @default.
• W2135198311 hasConceptScore W2135198311C2781303535 @default.
• W2135198311 hasConceptScore W2135198311C28328180 @default.
• W2135198311 hasConceptScore W2135198311C2994423619 @default.
• W2135198311 hasConceptScore W2135198311C30345302 @default.
• W2135198311 hasConceptScore W2135198311C502942594 @default.
• W2135198311 hasConceptScore W2135198311C530470458 @default.
• W2135198311 hasConceptScore W2135198311C553184892 @default.
• W2135198311 hasConceptScore W2135198311C71924100 @default.
• W2135198311 hasConceptScore W2135198311C86803240 @default.
• W2135198311 hasConceptScore W2135198311C88634738 @default.
• W2135198311 hasConceptScore W2135198311C95444343 @default.
• W2135198311 hasIssue "1" @default.
• W2135198311 hasLocation W21351983111 @default.
• W2135198311 hasLocation W21351983112 @default.
• W2135198311 hasLocation W21351983113 @default.
• W2135198311 hasLocation W21351983114 @default.
• W2135198311 hasOpenAccess W2135198311 @default.
• W2135198311 hasPrimaryLocation W21351983111 @default.
• W2135198311 hasRelatedWork W2032846010 @default.
• W2135198311 hasRelatedWork W2082436593 @default.

• next